Pharmacodynamic Models for Discrete DataPAULE, Ines; GIRARD, Pascal; FREYER, Gilles et al.Clinical pharmacokinetics. 2012, Vol 51, Num 12, pp 767-786, issn 0312-5963, 20 p.Article

Implementation of Validated Pharmacodynamic Assays in Multiple Laboratories: Challenges, Successes, and LimitationsKINDERS, Robert; FERRY-GALOW, Kate; LIHUA WANG et al.Clinical cancer research (Print). 2014, Vol 20, Num 10, pp 2578-2586, issn 1078-0432, 9 p.Article

Pharmacodynamic Biomarkers: Falling Short of the Mark?GAINOR, Justin F; LONGO, Dan L; CHABNER, Bruce A et al.Clinical cancer research (Print). 2014, Vol 20, Num 10, pp 2587-2594, issn 1078-0432, 8 p.Article

Rational therapeuticsWILLIAMS, R. L; BRATER, D. C; MORDENTI, J et al.Journal of medicine (Westbury). 1990, Vol 21, Num 3-4, issn 0025-7850, p. 219Article

Pharmacodynamic Effects in the Cardiovascular System: The Modeller's ViewFINK, Martin; NOBLE, Denis.Basic & clinical pharmacology & toxicology (Print). 2010, Vol 106, Num 3, pp 243-249, issn 1742-7835, 7 p.Conference Paper

Pharmacodynamic Effects of Haematopoietic Cytokines: The View of a Clinical OncologistHELD, Thomas K; GUNDERT-REMY, Ursula.Basic & clinical pharmacology & toxicology (Print). 2010, Vol 106, Num 3, pp 210-214, issn 1742-7835, 5 p.Conference Paper

Reporting a Population Pharmacokinetic-Pharmacodynamic Study: A Journal's PerspectiveJAMSEN, Kris M; McLEAY, Sarah C; BARRAS, Michael A et al.Clinical pharmacokinetics. 2014, Vol 53, Num 2, pp 111-122, issn 0312-5963, 12 p.Article

Pharmacokinetic and pharmacodynamic properties important for inhaled corticosteroidsHOCHHAUS, Gunther.Annals of allergy, asthma, & immunology. 2007, Vol 98, Num 2, issn 1081-1206, S7-S15, SUP2Article

Perfusion continue des bêtalactamines: intérêts, inconvénients, modalités pratiques : Infectieux = Continuous infusion of betalactam antibiotics: Interests, drawbacks, practical aspects : InfectiousJEHL, F; LEVEQUE, D.Réanimation (Paris. 2001). 2009, Vol 18, Num 4, pp 343-352, issn 1624-0693, 10 p.Article

Oncologic Phase 0 Trials Incorporating Clinical Pharmacodynamics : from Concept to Patient : FOCUSON Phase O Clinical trialsDOROSHOW, James H; PARCHMENT, Ralph E.Clinical cancer research. 2008, Vol 14, Num 12, pp 3658-3663, issn 1078-0432, 6 p.Article

Genesis of clinical pharmacokinetic/pharmacodynamic concepts : E.K. Marshall, Jr.'s roleLEVY, G.The Annals of pharmacotherapy. 1994, Vol 28, Num 11, pp 1300-1302, issn 1060-0280Article

Pharmacokinetic-pharmacodynamic modelling : History and perspectivesCSAJKA, Chantal; VEROTTA, Davide.Journal of pharmacokinetics and pharmacodynamics (Print). 2006, Vol 33, Num 3, pp 227-279, issn 1567-567X, 53 p.Article

Stereoselective drug disposition: potential for misinterpretation of drug disposition dataEVANS, A. M; NATION, R. L; SANSOM, L. N et al.British journal of clinical pharmacology. 1988, Vol 26, Num 6, pp 771-780, issn 0306-5251Article

Pharmacokinetic/Pharmacodynamic Modelling in Diabetes MellitusLANDERSDORFER, Cornelia B; JUSKO, William J.Clinical pharmacokinetics. 2008, Vol 47, Num 7, pp 417-448, issn 0312-5963, 32 p.Article

Barrière hématoencéphalique Partie III: approche thérapeutique pour franchir la barrière hématoencéphalique = Blood-brain barrier Part III: Therapeutic approaches to cross the blood-brain barrier and target the brainWEISS, N; MILLER, F; CAZAUBON, S et al.Revue neurologique (Paris). 2010, Vol 166, Num 3, pp 284-288, issn 0035-3787, 5 p.Article

Role of Microdialysis in Pharmacokinetics and Pharmacodynamics: Current Status and Future DirectionsAZEREDO, Francine Johansson; COSTA, Teresa Dalla; DERENDORF, Hartmut et al.Clinical pharmacokinetics. 2014, Vol 53, Num 3, pp 205-212, issn 0312-5963, 8 p.Article

ETUDE DE CERTAINS ESTERS DE LA RACINE DE CENTRANTHUS RUBER ET ACTION PHARMACODYNAMIQUE DE QUELQUES-UNES DE SES PREPARATIONS GALENIQUESADZET T; IGLESIAS J; SAN MARTIN R et al.1975; PLANTA MED.; ALLEM.; DA. 1975; VOL. 27; NO 2; PP. 194-198; ABS. ANGL.; BIBL. 14REF.Article

On the prediction of the human response : A recycled mechanistic pharmacokinetic/pharmacodynamic approachMENO-TETANG, Guy M. L; LOWE, Philip J.Basic & clinical pharmacology & toxicology (Print). 2005, Vol 96, Num 3, pp 182-192, issn 1742-7835, 11 p.Article

PHARMACODYNAMICS AND MARKERS OF DRUG EFFECTSGALEAZZI RL.1980; THER. DRUG MONIT.; USA; DA. 1980; VOL. 2; NO 1; PP. 11-17; BIBL. 23 REF.Article

INCONTRI ITALO-FRANCESI DI NEURORADIOLOGIA. I. TAVOLA ROTONDA. FARMACODINAMICA E QUADRI RADIOLOGICI DELLA VASOMOTILITA CEREBRALE. CAPRI; 1973 = RENCONTRES FRANCO-ITALIENNES DE NEURORADIOLOGIE. I. TABLE RONDE. PHARMACODYNAMIE ET TABLEAUX ANGIOGRAPHIQUES DE LA VASOMOTRICITE CEREBRALE. CAPRI; 19731974; ACTA NEUROL.; ITAL.; DA. 1974; VOL. 29; NO 2; PP. 105-226; BIBL. DISSEM.Conference Paper

Pharmacokinetic/pharmacodynamic modelling in oncological drug developmentKARLSSON, Mats O; ANEHALL, Therese; FRIBERG, Lena E et al.Basic & clinical pharmacology & toxicology (Print). 2005, Vol 96, Num 3, pp 206-211, issn 1742-7835, 6 p.Article

GENETIC INFLUENCES ON PHARMACODYNAMIC PROPERTIES OF PSYCHOTROPIC DRUGSPROPPING P; FRIEDL W.1979; PHARMACOLOGY; CHE; DA. 1979; VOL. 19; NO 1; PP. 1-4; BIBL. 23 REF.Article

Clinical Pharmacokinetics and Pharmacodynamics of Erythropoiesis-Stimulating AgentsDOSHI, Sameer; KRZYZANSKI, Wojciech; YUE, Susan et al.Clinical pharmacokinetics. 2013, Vol 52, Num 12, pp 1063-1083, issn 0312-5963, 21 p.Article

Development ofTranslational Pharmacokinetic-Pharmacodynamic ModelsMAGER, D. E; JUSKO, W. J.Clinical pharmacology and therapeutics. 2008, Vol 83, Num 6, pp 909-912, issn 0009-9236, 4 p.Article

Relations pharmacocinétique-pharmacodynamie des inhibiteurs de tyrosine kinases : Oncologie = Pharmacokinetics/pharmacodynamics relationship of tyrosine kinase inhibitorsBOUCHET, S.La Lettre du pharmacologue (Boulogne). 2010, Vol 24, Num 4, pp 121-128, issn 0984-452X, 8 p.Article